Nature Medicine publishes Helus Pharma’s randomized, placebo-controlled phase 2a trial of SPL026 in major depressive disorder
A Phase 2a trial of SPL026 demonstrated statistically significant and clinically meaningful reductions in depressive symptoms at two weeks, with effects lasting up to six months. The treatment was generally well-tolerated, and the findings provide clinical proof-of-concept for short-acting serotonergic modulation.